Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 24, 2010 Sean Williams	ViroPharma: Bargain or Value Trap? Generic competition and production issues are major red flags.
The Motley Fool March 20, 2006 Rich Duprey	ViroPharma's Generic Discount This tiny biotech looks cheap in light of sell-off over generics threat. Investors would do well to look a little closer at this promising biotech.
The Motley Fool November 3, 2006 Brian Lawler	Nothing's Wrong With ViroPharma Despite potential generic competition on the horizon, the company is going strong. Vancocin's fate will determine how well shares of ViroPharma perform in the near future.
The Motley Fool January 9, 2007 Brian Lawler	ViroPharma's Healthy Sales Guidance The coming year looks like another strong one for the drug developer. This small-cap pharmaceutical stock is worth taking a look at just for its cheap valuation.
The Motley Fool August 5, 2009 Brian Orelli	The Cash Cow Is Out of Milk ViroPharma has milked its antibiotic Vancocin, which it bought from Eli Lilly in 2004, pretty well, but it looks like the cash cow is finally running dry.
The Motley Fool February 28, 2008 Brian Lawler	ViroPharma in Check Sales of its antibiotic are slowing down, but there is a promising drug in its pipeline.
The Motley Fool November 21, 2007 Brian Lawler	Black Friday Bargain Stock: ViroPharma Is ViroPharma a good value right now? With competition worries out of the way, and a strong and growing cash flow, it won't take much success for value investors to be rewarded.
The Motley Fool April 30, 2008 Brian Lawler	ViroPharma: Risky and Exciting Solid lead drug, meet promising pipeline candidate.
The Motley Fool May 7, 2007 Brian Lawler	ViroPharma Victorious A strong first quarter helps the pharmaceutical storm into 2007. Investors, take note.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool March 2, 2007 Brian Lawler	Veering ViroPharma The drugmaker announces healthier fourth-quarter financial results. But investors take note: ViroPharma's product could have a formidable competitor on the market in 2008.
The Motley Fool May 29, 2009 Brian Orelli	The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin.
The Motley Fool July 9, 2008 Brian Lawler	ViroPharma Makes Its Case Rather than taking the more traditional route, ViroPharma has taken steps to try to make it significantly harder than normal for a generic-drug maker to attack its lead drug, Vancocin.
The Motley Fool April 4, 2011 Brian Orelli	Anti-Infective, Very Effective The FDA seems to like Optimer's new antibiotic.
The Motley Fool October 30, 2007 Brian Lawler	ViroPharma Gets No Respect The drugmaker announces third-quarter results; sales of its only marketed drug, antibiotic treatment Vancocin, fell due to a higher level of wholesaler stocking. Investors, take note.
The Motley Fool July 16, 2008 Brian Lawler	A Big Move From ViroPharma ViroPharma picks up an asset that's more than half its size.
The Motley Fool October 22, 2010 Brian Orelli	No Swelling Sales Here ViroPharma saw its stellar launch of hereditary angioedema treatment Cinryze come to a standstill until it could scale up manufacturing further.
The Motley Fool November 27, 2009 Brian Orelli	Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first.
The Motley Fool August 6, 2007 Brian Lawler	Don't Discount ViroPharma The exciting biopharma announces its second-quarter financial results. Considering that its lead drug is highly profitable and has two strong pipeline candidates in development, shares of ViroPharma don't look expensive.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool August 31, 2011 Brian Orelli	Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease.
The Motley Fool November 20, 2009 Kris Eddy	Drug Companies Targeted, Again Is a review of drug prices by Congress something to worry about?
The Motley Fool September 29, 2006 Brian Lawler	The Long Road Ahead for ViroPharma Faced with the threat of generic competition, the company focuses its efforts on a new drug. ViroPharma investors should watch intently.
The Motley Fool April 6, 2011 Brian Orelli	Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years.
The Motley Fool October 24, 2008 Brian Orelli	Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes.
The Motley Fool February 9, 2009 Brian Orelli	ViroPharma Cut in Half ViroPharma's phase 3 drug, maribavir, failed to show an effect in reducing cytomegalovirus (CMV) disease in stem cell transplant patients, and the stock gets axed in half.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
The Motley Fool May 26, 2009 Brian Orelli	Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected.
The Motley Fool May 31, 2011 Brian Orelli	Down! Up! Which Way Will Optimer Go Next? Long-term prospects look good.
The Motley Fool May 12, 2011 Brian Orelli	ViroPharma Gives It a Shot Testing a subcutaneous form of Cinryze.
The Motley Fool April 17, 2008 Brian Lawler	The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver.
The Motley Fool May 25, 2011 Brian Orelli	Optimer's Upcoming FDA Decision: Memorable or Memorial? We'll know on Memorial Day, plus or minus a few days.
The Motley Fool August 10, 2007 Brian Lawler	ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again.
The Motley Fool September 27, 2007 Brian Lawler	ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note.
The Motley Fool March 25, 2009 Brian Orelli	Wyeth: Now Approved to Kill More Bugs! Wyeth's antibiotic gets approved for another indication.
The Motley Fool October 3, 2007 Brian Orelli	Big Pharma Loves Your Liver Three big pharma companies, AstraZeneca, GlaxoSmithKline, and Roche, are funding a stem-cell consortium. Investors, take note.
The Motley Fool December 31, 2010 Seth Jayson	Here's How ViroPharma Is Making You So Much Cash With 27.0% of operating cash flow coming from questionable sources, ViroPharma investors should take a closer look at the underlying numbers.